...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes care >Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register
【24h】

Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register

机译：缩短的相对白细胞端粒长度与2型糖尿病中的普遍存存和事件心血管并发症相关：香港糖尿病寄存器的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE Several studies support potential links between relative leukocyte telomere length (rLTL), a biomarker of biological aging, and type 2 diabetes. This study investigates relationships between rLTL and incident cardiovascular disease (CVD) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Consecutive Chinese patients with type 2 diabetes (N= 5,349) from the Hong Kong Diabetes Register for whom DNA obtained at baseline was stored and follow-up data were available were studied. rLTL was measured by using quantitative PCR. CVD was diagnosed on the basis of ICD-9 code. RESULTS Mean follow-up was 13.4 years (SD 5.5 years). rLTL was correlated inversely with age, diabetes duration, blood pressure, HbA(1c), and urine albumin-to-creatinine ratio (ACR), and positively with estimated glomerular filtration rate (eGFR) (allP< 0.001). Subjects with CVD at baseline had a shorter rLTL (4.3 +/- 1.2 Delta Delta Ct) than did subjects without CVD (4.6 +/- 1.2 Delta Delta Ct) (P< 0.001). Of the 4,541 CVD-free subjects at baseline, the 1,140 who developed CVD during follow-up had a shorter rLTL (4.3 +/- 1.2 Delta Delta Ct) than those who remained CVD-free after adjusting for age, sex, smoking, and albuminuria status (4.7 +/- 1.2 Delta Delta Ct) (P< 0.001). In Cox regression models, shorter rLTL was associated with higher risk of incident CVD (for each unit decrease, hazard ratio 1.252 [95% CI 1.195-1.311],P< 0.001), which remained significant after adjusting for age, sex, BMI, systolic blood pressure, LDL cholesterol, HbA(1c), eGFR, and ACR (hazard ratio 1.141 [95% CI 1.084-1.200],P< 0.001). CONCLUSIONS rLTL is significantly shorter in patients with type 2 diabetes and CVD, is associated with cardiometabolic risk factors, and is independently associated with incident CVD. Telomere length may be a useful biomarker for CVD risk in patients with type 2 diabetes.
机译：目的几项研究支持相对白细胞端粒长度（RLT1），生物老化生物标志物之间的潜在环节，以及2型糖尿病。本研究研究了2型糖尿病患者RLTL和入射心血管疾病（CVD）之间的关系。研究设计和方法通过香港糖尿病患者连续患有2型糖尿病（n = 5,349）的患者，储存基线DNA的DNA和随访数据进行了研究。通过使用定量PCR来测量RLT1。 CVD在ICD-9代码的基础上诊断出来。结果平均随访时间为13.4岁（SD 5.5岁）。 RLT1与年龄，糖尿病持续时间，血压，HBA（1C）和尿白霉素至肌酐比（ACR）与估计的肾小球过滤速率（EGFR）相反相关，且均为丙二次）（ALLP <0.001）。基线中CVD的受试者比没有CVD的受试者更短的RLTL（4.3 +/- 1.2 delta ct）（4.6 +/- 1.2Δδct）（p <0.001）。在基线的4,541个无CVD主题中，在随访期间开发了CVD的1,140个，比在调整年龄，性别，吸烟和和留下的留下无CVD的那些较短的RLTL（4.3 +/- 1.2 delta ct）。白蛋白尿状态（4.7 +/- 1.2 Delta Delta CT）（P <0.001）。在Cox回归模型中，较短的RLT1与入射CVD的风险较高（对于每个单位减少，危险比1.252 [95％CI 1.195-1.311]，P <0.001），在调整年龄，性别，BMI后仍然显着，收缩压，LDL胆固醇，HBA（1C），EGFR和ACR（危害比1.141 [95％CI 1.084-1.200]，P <0.001）。结论RLT1患有2型糖尿病和CVD的患者显着较短，与心脏异常危险因素有关，并且与事件CVD独立相关。端粒长度可以是2型糖尿病患者CVD风险的有用生物标志物。

著录项

  • 来源
    《Diabetes care》 |2020年第9期|共9页
  • 作者

    Cheng Feifei; Luk Andrea O.; Tam Claudia H. T.; Fan Baoqi; Wu Hongjiang; Yang Aimin; Lau Eric S. H.; Ng Alex C. W.; Lim Cadmon K. P.; Lee Heung Man; Chow Elaine; Kong Alice P.; Keech Anthony C.; Joglekar Mugdha V.; So Wing Yee; Jenkins Alicia J.; Chan Juliana C. N.; Hardikar Anandwardhan A.; Ma Ronald C. W.;

  • 作者单位

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Univ Sydney Fac Med &

    Hlth NHMRC Clin Trial Ctr Sydney NSW Australia;

    Univ Sydney Fac Med &

    Hlth NHMRC Clin Trial Ctr Sydney NSW Australia;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Univ Sydney Fac Med &

    Hlth NHMRC Clin Trial Ctr Sydney NSW Australia;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

    Univ Sydney Fac Med &

    Hlth NHMRC Clin Trial Ctr Sydney NSW Australia;

    Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

    Therapeut Hong Kong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号